B2

to claim 1, and a pharmaceutically [acceptably] acceptable carrier.

7. (Twice amended) [Anti-idiotype monoclonal antibody 1A7] An antibody according to claim 1 wherein said antibody further comprises a detectable label.

B3

8. (Amended) [Anti-idiotype monoclonal antibody 1A7] An antibody according to claim 7, wherein said detectable label is selected from the group consisting of radiolabels, fluorescent labels and chemiluminescent labels.

9. (Amended) A diagnostic test kit for [the detection of melanoma and small cell carcinoma] detecting an anti-GD2 antibody in a biological sample, comprising [anti-idiotype monoclonal antibody 1A7] an antibody according to claim 1 in a suitable container.

Please cancel claims 2 and 3 without prejudice.
Please add the following claims:

-- 10. (Added) An antibody producing cell deposited under ATCC Accession No. HB-11786 and the progeny thereof.

B4

11. (Added) A purified antibody having identifying characteristics identical to an antibody produced by a cell according to claim 10.

12. (Added) Antibody purified from a cell according to claim 10.

13. (Added) The pharmaceutical composition of claim 4, wherein the antibody is capable of inducing an anti-GD2 antibody.

14. (Added) The pharmaceutical composition of claim 4, comprising an adjuvant.

B4 15. (Added) The pharmaceutical composition of claim 14, wherein the adjuvant is selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, and QS-21.

16. (Added) The pharmaceutical composition of claim 4, for treatment of a GD2 antigen associated cancer.

17. (Added) The pharmaceutical composition of claim 4, for treatment of melanoma, neuroblastoma, glioma, sarcoma, or small cell carcinoma.

Subt. C1 18. (Added) A pharmaceutical composition comprising an antibody according to claim 11.

19. (Added) The pharmaceutical composition of claim 18, comprising an adjuvant selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, and QS-21.

20. (Added) The diagnostic kit of claim 9, wherein the antibody is capable of binding anti-GD2.

21. (Added) The diagnostic kit of claim 9, wherein the antibody is labeled with a detectable label.

22. (Added) The diagnostic kit of claim 21, wherein the detectable label is selected from the group consisting of radiolabels, fluorescent labels, and chemiluminescent labels.

23. (Added) The diagnostic kit of claim 9, also comprising an anti-immunoglobulin reagent labeled with a detectable label.

24. (Added) The diagnostic kit of claim 9, wherein the biological sample is obtained from an individual suspected of having a GD2 antigen associated cancer.

25. (Added) The diagnostic kit of claim 9, wherein the cancer is obtained from an individual suspected of having a cancer selected from the group consisting of melanoma, neuroblastoma, glioma, sarcoma, and small cell carcinoma.

26. (Added) The diagnostic kit of claim 9, wherein the biological sample is obtained from an individual treated with monoclonal antibody 1A7. --

REMARKS

Claims 5-6 are withdrawn from consideration. Claims 1-4 and 7-9 are under examination and stand variously rejected. By this amendment, claims 2 and 3 are canceled; and new claims